NCT04088032 - Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer | Biotech Hunter

Timeline

Start Date

October 1, 2019

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions

Breast Cancer FemaleLocally Advanced Breast CancerHormone Receptor Positive Malignant Neoplasm of Breast

Interventions

DRUG

Abemaciclib, durvalumab and aromatase inhibitor

Subjects will receive standard therapy with an aromatase inhibitor (exemestane, anastrozole, or letrozole), combined with the experimental treatment of abemaciclib and durvalumab

Trial Locations (1)

11794

Stony Brook University Cancer Center, Stony Brook